Agilent Partners OmixAI to Expand AI-Driven Proteomics in South Korea

Agilent Partners with OmixAI to Expand AI-Driven Proteomics in South Korea

Joint development effort harnesses AI to enable large-scale analysis of complex biological data from living organisms that advances translational research in precision medicine

Agilent Technologies Inc. (NYSE: A) announced a three-year strategic collaboration with OmixAI to advance next-generation precision medicine through AI-driven proteomics research, strengthening Agilent's presence in fast-growing life sciences markets in Asia.

The collaboration focuses on the joint development of automated sample preparation workflows, integrating Agilent's Bravo Automated Liquid Handling Platform with OmixAI's proprietary multimodal database and AI-powered experimentation capabilities. The approach is designed to harness AI, enabling large-scale analysis of complex biological data from living organisms, helping generate actionable insights that advance translational research and drive long-term clinical impact.

Under the agreement, the companies will explore joint research initiatives in targeted protein degradation (TPD), biomarker discovery and emerging therapeutic modalities. The work aims to accelerate the identification of circulating biomarkers that may improve therapeutic outcomes. Both parties also plan to establish scalable, high-throughput standards for protein profiling across South Korea's research and biopharmaceutical ecosystems.

"We are thrilled to partner with Agilent to pioneer an innovative self-driving lab powered by Physical AI. By leveraging our proprietary The Cancer Surfaceome Atlas (TCSA) alongside Agilent's leading automation technology, we aim to drastically accelerate the development of next-generation ADC and TPD therapeutics. This collaboration reinforces our commitment to establishing South Korea as a global leader in AI-driven proteomics and precision medicine," said Park Jong Bae, Chief Technology Officer of OmixAI.

"South Korea is an important growth market for precision medicine, and this collaboration further positions Agilent to scale innovation with speed and rigor locally. Together with OmixAI, we are strengthening our differentiated portfolio by expanding cutting-edge, AI-enabled proteomics workflows that support translational research, paving the way to the development of future therapeutics and support long-term customer adoption and value creation," said Kang Hyun Hoo, Country General Manager of Agilent Technologies Korea.

For more than 25 years, Agilent has been supporting clinical labs to deliver safe and effective answers to real-world health questions worldwide. Agilent's presence in South Korea began in 1999 and has continued to invest in the market, including the acquisition of Young In Scientific in 2018 to strengthen its local capabilities.

Since then, the company has expanded its footprint through collaborations such as partnership with UBIX Therapeutics to advance transformative cancer research and by receiving MFDS approval in South Korea for Companion Diagnostic PD-L1 IHC 22C3 pharmDx on Dako Omnis to detect non-small cell lung cancer, demonstrating Agilent's innovative technology advances in supporting the most promising areas of medical research.